Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BI 1810631 disposition, mass balance, and absolute bioavailability in healthy men
NL-OMON59509Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zongertinib, sponsored by Boehringer Ingelheim. Primary endpoints: feurine, 0-tz, fefaeces, 0-tz and 1 more. Started Aug 2023; status: completed.
02
Drugs
zongertinib
Beyond the preview
Go deeper on NL-OMON59509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59509.